-
2024-514025-30-00
4
2021-03-25
Ocular conservative treatment for retinoblastoma
-
2023-505187-11-00
7
2021-03-01
Duchenne Muscular Dystrophy
-
2024-515019-22-00
5
2021-02-26
Septic shock
-
2024-511868-83-00
5
2021-02-05
Antisynthetase syndrome-related interstitial lung disease
-
2024-515384-62-00
5
2020-10-09
Soft Tissue Sarcoma
-
2023-507885-21-00
4
2020-08-18
Chronic Inflammatory Demyelinating Polyneuropathy
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2024-515276-12-00
5
2020-07-01
Postpartum Hemorrhage
-
2023-510567-35-00
4
2020-06-10
Advanced / metastatic cancers
-
2024-517185-42-00
3
2020-05-04
Children and teenagers with refractory/relapsing solid tumor
-
2024-514637-37-00
5
2020-02-11
Patients with bone sarcomas other than chordoma, who have no residual
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2024-514156-33-00
5
2019-08-20
Patients in remission for granulomatosis with polyangiitis (GPA,
Wegen
-
2023-508072-11-00
5
2019-06-26
Castration-resistant prostate cancer
-
2024-510580-28-00
5
2019-06-05
Middle or low locally advanced resectable rectal carcinoma
-
2023-508302-24-00
4
2019-05-07
Locally Advanced/Metastatic Urothelial Cancer
-
2024-512034-14-00
5
2019-03-04
severe trauma
-
2024-514094-22-00
5
2019-01-18
Intrecerebral Haemorrhage
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2024-514780-26-00
4
2018-10-23
Patients ≤50 years old with high-risk osteosarcoma (defined as metasta
-
2024-512827-36-00
4
2016-10-17
Penis carcinoma
-
2024-514791-40-00
9
2016-08-03
pediatric cancer
-
2024-516103-16-00
4
2015-12-04
Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)